| Reactive Astrocytes | |
|---|---|
| Lineage | Glia > Astrocyte > Reactive |
| Markers | GFAP, C3, S100B, ALDH1L1, AQP4 |
| Brain Regions | Brain Parenchyma, Cortex, Hippocampus, Substantia Nigra |
| Disease Associations | Alzheimer's Disease, Parkinson's Disease, ALS, MS, Brain Injury, Stroke |
| Classification | A1 (Neurotoxic), A2 (Neuroprotective) |
Reactive Astrocytes Overview plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Reactive astrocytes are astrocytes that have undergone morphological and molecular changes in response to CNS injury, infection, or disease. Once considered merely scar-forming cells, reactive astrocytes are now recognized as versatile players in both neurodegeneration and neuroprotection[1].
The reactive astrocyte phenotype was first described in the late 19th century by Rudolf Virchow, who coined the term "reizbare Gliose" (irritated gliosis). Modern single-cell RNA sequencing has revealed remarkable heterogeneity in reactive astrocyte populations, leading to the A1/A2 classification paradigm introduced by Liddelow and Barres in 2017[2].
A1 astrocytes are induced by microglial release of the complement component C1q, IL-1α, and TNF. These cells:
Molecular signature: C3, SERPINA3N, GFAP, ligp1, Amigo2
A2 astrocytes are induced by ischemia and upregulate genes involved in tissue repair:
Molecular signature: S100A10, PTX3, CD14, Emp1, Tm4sf1
Reactive astrocytes undergo characteristic morphological transformations:
These changes can be visualized using GFAP immunohistochemistry, though GFAP expression alone does not distinguish between A1 and A2 phenotypes.
Reactive astrocytes retain many normal astrocyte functions while acquiring new capabilities:
Reactive astrocytes in AD exhibit both beneficial and harmful effects:
Neurotoxic A1 polarization:
Neuroprotective responses:
In PD, reactive astrocytes:
Astrocyte reactivity in ALS:
In MS lesions:
Reactive Astrocytes Overview plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Reactive Astrocytes Overview has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent studies presented at conferences including AAIC 2026 have advanced our understanding of astrocyte reactivity in neurodegeneration:
These findings highlight the importance of astrocyte-targeted therapeutic strategies for Alzheimer's disease[3][4].
Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev. 2014. 2014. ↩︎
Liddelow SA, Barres BA. Reactive astrocytes: production, function, and regulation. Immunity. 2017. 2017. ↩︎
Liddelow KA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017. 2017. ↩︎
Escartin C, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021. 2021. ↩︎